Accepted at 5:21 p.m. Jun, 05, 2025 by andrewmathias8
Author: andrewmathias8
Related Note: 1509300563305
Rationale for change

UWorld Step 2 id:20700 says that "patients may develop recurrent symptoms 5-14 days after each dose of [chimeric monoclonal antibodies]."

Additionally, AMBOSS does not support a specific 7-10 day timeline, and rather states, "Symptoms appear 1–3 weeks following initial exposure (because antibodies take several days to form) and typically resolve within a few weeks after discontinuation of the offending agent."

FA25 pg 111 also says "Fever, urticaria, arthralgia, proteinuria, lymphadenopathy occur 1–2 weeks after antigen exposure."

Source: AMBOSS - https://next.amboss.com/us/article/Vt0Gc3?utm_source=amboss-anki-deck-template-script&utm_medium=anki&utm_campaign=amboss-anki-deck-template-script-beta&utm_term=serum+sickness&aid=298bfc66-b119-4c76-b7ef-8bfc7d192ab2&uid=ptfeLeLy0#Za175872da7e10019b960c6b80f28b3ba

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::19_Rituximab #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::02_Monoclonal_Antibody_Therapy #AK_Step2_v12::#UWorld::COMLEX::108595 #AK_Step1_v12::#UWorld::COMLEX::106913 #AK_Step1_v12::#Bootcamp::Immunology::11_Hypersensitivities::04_Type_III_Hypersensitivity_Reactions #AK_Step1_v12::#UWorld::COMLEX::23853 #AK_Step1_v12::#UWorld::Step::741 #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::17_Cetuximab/Panitumumab #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::18_Anticancer_monoclonal_antibodies::*Rituximab::Basics #AK_Step1_v12::#Physeo::09_Pharm::09_Musculoskeletal::09_TNF-alpha_Inhibitors #AK_Step1_v12::#B&B::13_Immunology::02_Clinical_Immunology::01_Hypersensitivity::Extra #AK_Step1_v12::#Pixorize::03_Pharmacology::13_Musculoskeletal_Pharm::12_TNF_Inhibitors_((Infliximab/Adalimumab/Certolizumab/Golimumab) #AK_Step1_v12::#Bootcamp::Musculoskeletal::15_Pharmacology::07_TNF_Alpha_Inhibitors_And_Monoclonal_Antibodies #AK_Step2_v12::#NBME::Form11::Section_1 #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#UWorld::Step::7656 #AK_Step1_v12::#OME::PreClinical::Immunology #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::18_Anticancer_monoclonal_antibodies::*Cetuximab_Panitumumab #AK_Step2_v12::#UWorld::Step::20700 #AK_Step2_v12::#B&B::08_Infectious_Disease::01_Antibiotics::01_Penicillins::Extra #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies::*Basics